Ballicules.com

Bumetanide

BUMEX

What it isNKCC2-inhibiting loop diuretic; edema and volume overload in heart failure or kidney disease.

Why this oneOral bioavailability near 80%, far more reliable than furosemide, and it is about 40 times more potent milligram for milligram.

What limits itSame electrolyte losses as the class. The potency ratio is the usual source of dosing error when converting from furosemide.

FDA-approved for

FDA label

BOXED WARNING Potent diuretic; excessive amounts can cause profound diuresis with water and electrolyte depletion — careful supervision and individualized dosing required
FDA dosingPopulationStartTargetMax
EdemaAdults0.5–2 mg QD0.5–2 mg QD (single dose)10 mg/day

Renal Contraindicated in anuria; discontinue if marked rise in BUN/creatinine or oliguria in progressive renal disease

Hepatic Keep dosage to a minimum in hepatic failure

If initial dose inadequate, a 2nd or 3rd dose may be given at 4–5 hour intervals up to max 10 mg/day

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy No adequate human studies; use only if potential benefit justifies fetal risk

Lactation Undefined

NO BOXED WARNINGS

Principal riskVolume depletion with hypokalemia

Cost, est. cash$5–$150/month

Generic entry1994

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger3 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityVolume depletion, electrolyte loss, kidney injury and ototoxicity at high exposure.

Mechanism of action: Bumetanide ballicule

Bumetanide ballicule: receptor binding, kinetics and half-life diagram

Open Bumetanide in the interactive console ↗

Memory aids: mascots and interaction avatars

Bumetanide BUMEX mascot mnemonic cartoon
“Bum Bummer”
Bananas dispersing → ↓ serum potassium
Bumetanide CYP3A4 substrate avatar
CYP3A4 substrate (minor)

Open Bumetanide in the interactive console ↗